Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1 (ARTISTRY-2)
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH). The primary objective of this study is to learn how effective it is to switch to BIC/LEN FDC tablets versus continuing on B/F/TAF FDC tablets in virologically suppressed PWH.
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
HIV-1-infection
Gender
N/A
Date
March 2024 - December 2025
Study Type
Interventional
Study Phase
Phase 3
Product
Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN
Los Angeles, California, United States, 90036
Fort Lauderdale, Florida, United States, 33308
Fort Pierce, Florida, United States, 34982
Decatur, Georgia, United States, 30033
Saint Louis, Missouri, United States, 63139
Somers Point, New Jersey, United States, 08244
Houston, Texas, United States, 77098
Share Trial